Going Gangbusters on Stroke
This article was originally published in Start Up
Executive Summary
The field of acute ischemic stroke is highly promising but enormously risky and fraught with disappointment. With the exception of tPA, no one has ever demonstrated a pharmaco-mechanism which produces efficacy in the clinic. For now, the key to success for companies will be good efficacy and safety data. Start-ups will need partners, but even alliances with major pharmaceutical companies don’t represent a short-term validation of their efforts, since even big companies are stumbling in this field.
You may also be interested in...
Interventional Neuroradiology's Growing Pains
Neuroendovascular devices for treating hemorrhagic and ischemic stroke, while investigational, are gaining attention because of technology advances, intriguing anecdotal evidence of efficacy in a field in which previous drug therapies haven't worked, and positive but controversial emerging clinical data. Companies are pursuing neuro applications of endovascular devices, but despite lots of noise, clinical challenges and uncertain market potential restrain many from investing heavily in the field.
Interventional Neuroradiology's Growing Pains
Neuroendovascular devices for treating hemorrhagic and ischemic stroke, while investigational, are gaining attention because of technology advances, intriguing anecdotal evidence of efficacy in a field in which previous drug therapies haven't worked, and positive but controversial emerging clinical data. Companies are pursuing neuro applications of endovascular devices, but despite lots of noise, clinical challenges and uncertain market potential restrain many from investing heavily in the field.
Persistently Seeking Stroke Solutions
Even as ischemic stroke researchers debate what went wrong following a string of high-profile, expensive clinical trial failures, they're optimistic that advances in understanding of the disease and application of lessons learned from past mistakes will yield more effective therapies.